Drugs / JV-GL1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04761705 | Mar 2021 → Mar 2025 | ocular hypertension, open-angle glaucoma | JeniVision, Inc. | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JV-GL1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04761705 ↗ |
| Route | Topical | “JV-GL1 Applied to the Periorbital Skin” NCT04761705 ↗ |